68754-16-5

Upstream product

• 26103-97-9 phloroisovalerophenone 
• 77-78-1 dimethyl sulfate 
• 186581-53-3 diazomethane 
• 503-74-2 3-methylbutyric acid 
• 500-99-2 3,5-dimethoxyphenol 
• 108-73-6 3,5-dihydroxyphenol 
• 108-12-3 isopentanoyl chloride 
• 590-86-3 isovaleraldehyde 

Downstream Products

• 68754-17-6 2-(3-methylbutyl)-3,5-dimethoxyphenol 
• 179630-54-7 2-hydroxy-4,6-dimethoxy-3-(3-methylbutanoyl)benzaldehyde 
• 167385-77-5 2-(1-Hydroxy-3-methyl-butyl)-3,5-dimethoxy-phenol 
• 68754-19-8 2,4-Dimethoxy-benzoic acid 3,5-dimethoxy-2-(3-methyl-butyl)-6-(5-methyl-hexanoyl)-phenyl ester 
• 68754-20-1 1-(2,4-Dimethoxy-phenyl)-3-[2-hydroxy-4,6-dimethoxy-3-(3-methyl-butyl)-phenyl]-2-(3-methyl-butyl)-propane-1,3-dione 
• 68754-18-7 1-[2-Hydroxy-4,6-dimethoxy-3-(3-methyl-butyl)-phenyl]-5-methyl-hexan-1-one 
• 179630-66-1 1-(2-Hydroxy-4,6-dimethoxy-3-propylsulfanylmethyl-phenyl)-3-methyl-butan-1-one 
• 167385-76-4 3,5-Dimethoxy-2-(3-methyl-1-phenylsulfanyl-butyl)-phenol 

Relevant academic research and scientific papers

A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway

Numerous drug treatments are available for Parkinson's disease (PD), an age-related neurodegenerative disease, but most cause serious side effects. Therefore, novel therapeutic strategies that halt disease progression and allow for long-term administration are urgently needed. Neuroinflammation critically contributes to the pathogenesis of PD. Here, we report the discovery and optimization of phloroglucinol derivatives, a novel class of anti-neuroinflammatory compounds. Structural modifications of the hit compound 3-methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one produced 43 derivatives, including a preclinical candidate (compound 21), that exhibited potent in vitro anti-neuroinflammatory effects, good blood-brain barrier penetration, and desirable safety margins in mice at a median lethal dose (LD50) >5000 mg/kg. Its in vivo efficacy was demonstrated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- and MPTP/probenecid (prob)-induced subacute and chronic PD models, respectively, and α-synuclein transgenic mice. Mechanistic studies revealed neuroinflammation inhibition by targeting Src/phosphatase and tensin homologue deleted on chromosome 10 (PTEN)/Akt signaling might be promising. We highlighted the potential usefulness of phloroglucinol derivatives in PD treatment.

Synthesis of 2-acylphenol and flavene derivatives from the ruthenium-catalyzed oxidative c-h acylation of phenols with aldehydes

The cationic ruthenium hydride complex [(C6H6)(PCy3)(CO)RuH]+BF4- has been found to be an effective catalyst for the oxidative C-H coupling reaction of phenols with aldehydes to give 2-acylphenol compounds. The coupling of phenols with α,β-unsaturated aldehydes selectively gives the flavene derivatives. The catalytic method mediates direct oxidative C-H coupling of phenol and aldehyde substrates without using any metal oxidants or forming wasteful byproducts. A cationic ruthenium hydride complex catalyzes the oxidative C-H coupling of phenols with aldehydes to form 2-acylphenol and flavene derivatives.

The first total synthesis of sideroxylonal B

Sideroxylonal B (2c) has been synthesized through biomimetic cycloaddition of the o-quinone methide and the isopentenyl intermediates (5 and 6t), both of which were simultaneously derived from isopentenyl phloroglucinol precursor 4.

Electrochemical synthesis of chroman and euglobal skeletons via cycloaddition reaction of o-quinone methides and alkenes

Euglobal skeletons were synthesized by the intermolecular cycloaddition reaction of terpenes and o-quinone methides generated in situ by electrochemical oxidation. In a two-phase reaction medium composed of hexane-lithium perchlorate/nitromethane, 2-[1-(p